Pancreatic Neoplasm Clinical Trial
Official title:
Multicolour Versus Monocolour Inking Specimens After Pancreaticoduodenectomy for Periampullary Cancer: a Single Center Prospective Randomised Clinical Trial.
A single-centre, randomised clinical trial of patients affected by periampullary cancer who underwent pancreaticoduodenectomies which included two different types of specimen margination: arm A (multicolour inking) and arm B (monocolour inking). The randomisation of the specimen was made after the resection, blinded for the surgeons involved in the operation. The primary endpoint was the overall R1 resection rate and its difference between the two arms. The secondary endpoints were the R1 resection rate in each margin and its difference between the two arms, and the impact of margin status on survival. A sample size of 18 patients was required.
This study was a single-centre, prospective, controlled, open, parallel group, randomised
clinical trial, conducted in the tertiary referral University Centre of S.Orsola-Malpighi
Hospital, Bologna, Italy, from June 2012 to January 2016, which enrolled patients affected
by periampullary cancer who underwent pancreaticoduodenectomy (PD). All patients with
suspected periampullary cancer were enrolled in the study, but only patients who underwent
pancreaticoduodenectomy were randomised and allocated to a multicolour inking specimen (arm
A, experimental) or a monocolour inking (arm B, control) after specimen was taken out from
the operative field. The analysis regarded only the specimens of the patients who underwent
PD in which the final pathologic report showed a diagnosis of invasive periampullary cancer
(pancreatic, ampullary and distal bile duct).
After performing the pancreaticoduodenectomies, the surgeon intraoperatively inked the
surfaces/margins of the specimen with different colours. In the multicolour arm, the
surfaces/margins inked were the following: Anterior surface of the pancreas (yellow);
Posterior surface of the pancreas (orange); Superior mesenteric/portal vein groove (blu);
Superior mesenteric artery margin (retroperitoneal margin) (red); Transection margin of the
bile duct (green).The trans-section pancreatic and gastric margins were not inked.
In the monocolour arm, only the superior mesenteric artery margin and the pancreatic margin
were intraoperatively indicated by the surgeon in the specimen: a single stitch to identify
the transection pancreatic margin and a continuous suture to identify the superior
mesenteric artery margin. Monochromatic inking of the superior mesenteric artery margin was
subsequently carried out by the pathologist. In both arms of treatment, the macroscopic
evaluation and slicing of the surgical specimen followed the Leeds Pathology Protocol
(LEEPP), and seven margins, which included the anterior, posterior, superior mesenteric
/portal vein groove, superior mesenteric artery, bile duct, pancreatic neck and stomach
margins, were examined. The primary endpoint was to evaluate the overall R1 resection rate
and its difference between multicolour (arm A) and monocolour (arm B) inking of the
specimen. The secondary endpoints were to evaluate the R1 resection rate in each margin:
anterior and posterior surfaces of the pancreatic head; superior mesenteric/portal vein
groove; superior mesenteric artery margin; transection pancreatic and bile duct margins, and
its difference between the two arms compared. Finally, the impact of the margin status on
survival was considered for each margin and type of periampullary tumours.
Calculation of the sample size was based on the literature assumption that the overall
incidence rate expected of R1 ranged from 10 to 76% while it increased to 81-85% when a
standardised pathological technique and margination with multicolour inking, as described in
arm A, was performed. To detect a difference in R1 rate between these values with a 5%
alpha-error and a 80% beta-error at a two-sided 0.05 significance level, a sample size of 18
patients was required for each group. In relation to the fact that the patients were often
randomised without a preoperative biopsy, and that following current literature the 5-13% of
the presumed malignancies were benign, it was decided to randomise 25 patients in order to
avoid a sample size smaller than expected. The sample size calculation was carried out using
PS Power and Sample Size Calculation software (Department of Biostatistics; Vanderbilt
University; Nashville, TN, USA).
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01354795 -
Prospective Study Comparing Methods of Obtainment of Specimen After EUS-FNA in Patients With Peri-pancreatic Mass
|
N/A | |
Completed |
NCT00958841 -
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
|
Phase 2 | |
Terminated |
NCT00249301 -
A Study of MLN8054 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06122896 -
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
|
Early Phase 1 | |
Terminated |
NCT02602067 -
131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients
|
Phase 1 | |
Recruiting |
NCT06411795 -
Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy
|
Phase 2 | |
Completed |
NCT03622229 -
EUS-FNB for Solid Pancreatic Lesions: Side-fenestrated Vs Fork-tip Needle
|
N/A | |
Recruiting |
NCT06400472 -
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT02791503 -
CROSSFIRE Trial: Comparing the Efficacy of Irreversible Electroporation With Radiotherapy
|
N/A | |
Recruiting |
NCT05786716 -
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations
|
Phase 2/Phase 3 | |
Completed |
NCT03322592 -
EUS-FNB With ROSE Vs. EUS-FNB Without ROSE
|
N/A | |
Completed |
NCT05745415 -
Cancer Stem Cell Specific Aptamer's Ability to Detect Blood Circulating Cancer Stem Cells and Its Role as a Predictor of Prognosis in Pancreatic Cancer
|
||
Recruiting |
NCT05083247 -
Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma
|
Phase 2 | |
Completed |
NCT00436423 -
A Phase Ⅱ Study of Gemcitabine Combination With TS-1 in Patient With Advanced or Recurred Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT00711191 -
A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas
|
Phase 1 | |
Completed |
NCT00222898 -
Cancer Detection in Pancreatic Cysts
|
N/A | |
Completed |
NCT00034281 -
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2
|
Phase 1 | |
Completed |
NCT00005926 -
Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas
|
Phase 2 | |
Recruiting |
NCT04164017 -
Impact of Suction in the EUS-guided Fine Needle Biopsy of Solid Pancreatic Lesions
|
N/A | |
Recruiting |
NCT05687123 -
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
|
Phase 1 |